Pharma

An additional treatment option with TAGRISSO® (osimertinib)


Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO® (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients.

Listen to the full podcast episode to learn more. 

Please see Important Safety Information for TAGRISSO.

Please see complete Prescribing Information, including Patient Information for TAGRISSO.

 

                 

AstraZeneca
The editorial staff had no role in this post's creation.